At the end of 2018, the National Information Center and China Economic Information Network released the "2019 Pharmaceutical Industry Development Report - Prospects: Strict Control Fees, Drug-Reducing Prices, Innovative Medicines, and High-quality Generics Will Stand Out" (the following texts are referred to as "Reports") ). The "Report" looks forward to the growth of investment in the pharmaceutical industry in 2019. It is estimated that the fixed assets investment in the pharmaceutical manufacturing industry will reach about 678.2 billion yuan in 2019, an increase of about 10%.
According to the "Report", since 2018, under the influence of factors such as the comprehensive promotion of consistency evaluation, the initial implementation of the new classification reform plan for chemical drug registration, and the process of verification of drug clinical trial data, most enterprises have been affected andProduction kinetic energy has declined.
The income of the main business of the pharmaceutical industry maintained rapid growth, mainly due to the volume of bidding for some products of pharmaceutical enterprises and the new medical insurance. The change in the marketing model of medicines led to an increase in apparent income and the price increase of some products.
In 2019, the supply side will be affected by factors such as consistency evaluation work, drug listing permit holder system, and quality supervision. The pharmaceutical industry will control the number of existing drug varieties and even existing drug manufacturers, from optimizing stock varieties and optimizing stocks. The manufacturer's perspective purifies the industry, optimizes the competitive environment, reduces the low-end supply and inefficient supply in the pharmaceutical sector, and achieves the goal of de-capacity. At the same time, it strengthens the guidance for R&D, accelerates review and approval, and optimizes the policy environment to encourage innovation.